Lexicon Pharmaceuticals
Clinical trials sponsored by Lexicon Pharmaceuticals, explained in plain language.
A biopharmaceutical company developing treatments for diabetes and other diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a diabetes drug help heart muscle disease? large trial underway Results expected Jan 2027 (estimated) 🚀 Make-or-break
-
New drug shows promise for shingles nerve pain
Symptom relief CompletedThis study tested an experimental drug called LX9211 in 79 adults with postherpetic neuralgia, a type of nerve pain that can last for months after a shingles rash heals. The goal was to see if the drug reduces pain and helps with sleep compared to a placebo over 11 weeks. Partici…
Phase 2 • Sponsor: Lexicon Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
New drug LX9211 aims to ease diabetic nerve pain
Symptom relief CompletedThis study tested a drug called LX9211 in 496 adults with diabetic peripheral neuropathic pain (nerve pain from diabetes). The goal was to see if it reduces average daily pain and improves sleep compared to a placebo over 8 weeks. The trial is complete, and results will show if L…
Phase 2 • Sponsor: Lexicon Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 07:54 UTC